Cytokine Gene Therapy for Malignant Pleural Mesothelioma

Slides:

Advertisements

Similar presentations

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.

Advertisements

High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma Masaki Nasu, Mitsuru Emi, Sandra Pastorino, Mika Tanji, Amy Powers, Hugh.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

ALK FISH and IHC: You Cannot Have One without the Other

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

Pleural Fluid Cytological Yield and Visceral Pleural Invasion in Patients with Epithelioid Malignant Pleural Mesothelioma Valentina Pinelli, MD, Sophie.

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Hedgehog Signaling Pathway and Lung Cancer

The Moth-Eaten Lung Journal of Thoracic Oncology

An Unusual Presentation of Malignant Pleural Mesothelioma

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

Takehito Shukuya, MD, PhD, David P. Carbone, MD, PhD

Robert J Korst, MD, Ronald G Crystal, MD

Frank Detterbeck, MD Journal of Thoracic Oncology

Alterations of the Immune System in Thymic Malignancies

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Immuno-gene therapy with interferon-β before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma Robert.

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

STAT3, Cten, and lung cancer: Simultaneous excitement and caution

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Valder R Arruda, Patricia Favaro, Jonathan D Finn Molecular Therapy

In This Issue Journal of Thoracic Oncology

Immunotherapy for Lung Cancer

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Heidi B. Rolke, Frode Gallefoss Journal of Thoracic Oncology

Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study Gunnar Hillerdal, MD, PhD, Jens.

Mitotic Inhibitors Journal of Thoracic Oncology

Ayman O. Soubani, MD, John C. Ruckdeschel, MD

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Daniel B. Costa, MD, PhD, Susumu Kobayashi, MD, PhD

MTP13-01: Indications and limitations of bronchoscopy

Multiple Primary Cancers or Multiple Metastases, That Is the Question

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma Zacariah E. Labby, PhD, Samuel G. Armato, PhD,

Phase I Study of Lenalidomide in Solid Tumors

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Silvia Bielsa, MD, José Martín-Juan, MD, José M

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide

In This Issue Journal of Thoracic Oncology

Table of Contents Journal of Thoracic Oncology

International Thymic Malignancies Interest Group: A Way Forward

Linda L. Garland, MD, Kari Chansky, MS, Antoinette J

European Lung Cancer Conference (ELCC) 2016 Organisation

A Pathological Complete Response in Malignant Pleural Mesothelioma after Combination Chemotherapy with Carboplatin and Pemetrexed Steven Chuan-Hao Kao,

Pleural Metastases of Malignant Melanoma

IASLC 6th Latin American Conference on Lung Cancer

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Epidemiology of Thymoma and Associated Malignancies

Induction Therapy For Locally Advanced Thymoma

Debby P. M. van den Bogaert, MD, Ellen M

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Cytokine Gene Therapy for Malignant Pleural Mesothelioma Anil Vachani, MD, Daniel H. Sterman, MD, Steven M. Albelda, MD Journal of Thoracic Oncology Volume 2, Issue 4, Pages 265-267 (April 2007) DOI: 10.1097/01.JTO.0000263706.23579.35 Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Antitumor mechanisms of interferon (IFN)-β gene therapy for malignant pleural mesothelioma. IFN-β has direct effects on the tumor and multiple effects leading to activation of the immune response. MHC, major histocompatibility complex; CTL, cytotoxic T-lymphocyte; NK, natural killer. Journal of Thoracic Oncology 2007 2, 265-267DOI: (10.1097/01.JTO.0000263706.23579.35) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions